Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2012
05/10/2012WO2012061342A2 Substituted benzo-imidazo-pyrido-diazepine compounds
05/10/2012WO2012061337A1 Fgfr2 modulators
05/10/2012WO2012061169A1 Benzimidazole inhibitors of leukotriene production
05/10/2012WO2012061113A2 Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis
05/10/2012WO2012061086A2 Method of treating neuroendocrine tumors
05/10/2012WO2012061015A2 L-citrulline supplementation during arginine depletion therapy with arginase
05/10/2012WO2012061012A2 4-amino-2h-pyran-2-one analogs as anticancer agents
05/10/2012WO2012060707A1 Microsphere comprising a lanthanide metal complex
05/10/2012WO2012060482A1 Cdk-inhibiting pyrrolopyrimidinone carboxamide derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient for preventing or treating liver cell cancer
05/10/2012WO2012060480A1 Antigen peptide for suppressing metastasis, anti-metastatic vaccine including same, composition for suppressing and treating metastasis, and method for screening metastasis-related target materials and metastasis suppressant
05/10/2012WO2012059941A1 Process for preparation of sunitinib malate and salts thereof
05/10/2012WO2012059935A1 Process for preparing bendamus tine hydrochloride monohydrate
05/10/2012WO2012059932A1 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
05/10/2012WO2012059857A2 Pan-her antibody composition
05/10/2012WO2012059725A1 Peg or peg block copolymers for treating colorectal cancer
05/10/2012WO2012059572A1 COMBINATION OF ATOMIC QUANTUM CLUSTERS (AQCs) AND ANTINEOPLASIC DRUGS, AND ITS USE IN THE PREVENTION AND/OR TREATMENT OF CELL PROLIFERATIVE DISORDERS
05/10/2012WO2012059568A1 Novel water-soluble indolobenzazepine molecules demonstrating antimitotic, antivascular, and antitumor activities in vivo
05/10/2012WO2012059562A1 C-met antibody combinations
05/10/2012WO2012059561A1 Anti c-met antibodies
05/10/2012WO2012059543A1 Composition containing calcium carbonate
05/10/2012WO2012059526A1 Treatment of mastocytosis with masitinib
05/10/2012WO2012059515A1 Kit for the localized activation of high concentrations of a drug and the procedure thereof
05/10/2012WO2012059507A1 Pyrrolidine derivatives used as cathepsin inhibitors
05/10/2012WO2012059232A1 Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
05/10/2012WO2012059224A1 Immunotherapy against erbb-3 receptor
05/10/2012WO2012059172A1 1h-pyrrolo[2,3-b]pyridine derivatives
05/10/2012WO2012059041A1 Novel 6-arylamino pyridone carboxamide as mek inhibitors
05/10/2012WO2012059001A1 Imidazole derivatives and preparation method and use thereof
05/10/2012WO2012058866A1 Benzamide derivative with anticancer activity and preparation method and use thereof
05/10/2012WO2012058768A1 Stable heterodimeric antibody design with mutations in the fc domain
05/10/2012WO2012058763A1 Synthetic lethality in cancer
05/10/2012WO2012037410A9 Estrogen receptor modulators and uses thereof
05/10/2012WO2012036392A3 Human anti-epidermal growth factor receptor fab antibody and a pharmaceutical composition for treating tumours comprising the same
05/10/2012WO2012031103A3 Inhibitors of bcl-2
05/10/2012WO2012027482A3 Compounds, compositions and methods related to ppar antagonists
05/10/2012WO2012027324A3 Treatment for neoplastic diseases
05/10/2012WO2012021016A3 Lactobacillus strain having anti-cancer activity and anti-cancer activity composition including same as active ingredient
05/10/2012WO2012020021A9 Glycyrrhetinic acid amine analogues for use in the treatment of inflammation, infectious diseases, cancer, autoimmune diseases, skin diseases, bone diseases and metabolic diseases
05/10/2012WO2012019430A8 Phthalazinone derivative, and preparation method and pharmaceutical use thereof
05/10/2012WO2012019427A8 Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
05/10/2012WO2012019426A8 Phthalazinone derivative, and preparation method and pharmaceutical use thereof
05/10/2012WO2012018932A3 Compounds and compositions for mitigating tissue damage and lethality
05/10/2012WO2012018383A3 Interior functionalized hyperbranched dendron-conjugated nanoparticles and uses thereof
05/10/2012WO2012018380A3 Compositions and methods for inducing immune tolerance
05/10/2012WO2012011952A9 Copy number variant-dependent genes as diagnostic tools, predictive biomarkers and therapeutic targets
05/10/2012WO2011146819A3 METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES
05/10/2012WO2011146589A3 Vitamin e conjugates, and their uses as antioxidants and prodrug delivery vehicles
05/10/2012WO2011110842A3 Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome
05/10/2012WO2010069532A8 Antibodies against human angiopoietin 2
05/10/2012US20120117672 Isolation and growth of stem cells from hemangiomas
05/10/2012US20120117670 Humanized axl antibodies
05/10/2012US20120116287 Photolabile compounds
05/10/2012US20120116052 Nucleic Acid Molecules Encoding TNF-Alpha Ligand Polypeptides Having a CD154 Domain
05/10/2012US20120116051 Polymer Conjugate Of Bioactive Substance Having Hydroxy Group
05/10/2012US20120115955 Methods for tumor treatment and adipogenesis differentiation
05/10/2012US20120115935 Anti-cancer agent, method for inducing apoptosis of cancer cells, and method for screening for anti-cancer agent
05/10/2012US20120115928 Mirna and its targets respectively the proteins made based on the targets as a prognostic, diagnostic biomarker and therapeutic agent for cancer
05/10/2012US20120115922 Smac mimetec
05/10/2012US20120115915 N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
05/10/2012US20120115906 Derivatives of 3-alkoxy-4,5-diarylthiophene-2-carboxamide, preparation thereof, and therapeutic use thereof
05/10/2012US20120115905 Nitrone, Nitroso, and Nitroxide Spintraps and Spin Labels and Their Hydroxylamines
05/10/2012US20120115902 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents
05/10/2012US20120115898 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof
05/10/2012US20120115897 Aryl (Ethanoic) Propanoic Acid Ascorbyl Ester, Preparation Method Thereof And Medicament Containing The Same
05/10/2012US20120115896 Isogenic human cell lines comprising mutated cancer alleles and process using the cell lines
05/10/2012US20120115892 Administration of nedd8-activating enzyme inhibitor
05/10/2012US20120115890 Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith
05/10/2012US20120115883 Pyrimidine derivatives which are antagonists of the vitronectin receptor
05/10/2012US20120115880 Method for Treating Ocular Cancer
05/10/2012US20120115878 Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
05/10/2012US20120115877 Facially Amphiphilic Compounds, Compositions, And Uses Thereof In Treating Cancer
05/10/2012US20120115874 Pyrazine derivatives, process for manufacture and use thereof
05/10/2012US20120115873 Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting parp
05/10/2012US20120115867 New class of histone deacetylase inhibitors
05/10/2012US20120115866 Kinase inhibitor compounds
05/10/2012US20120115864 Substituted Fused Pyrimidine Compounds
05/10/2012US20120115861 Aminopyridine derivatives for treating tumors and inflammatory diseases
05/10/2012US20120115858 Polymorph Form II of Tanaproget
05/10/2012US20120115852 Heterocyclic compounds as autotaxin inhibitors
05/10/2012US20120115850 Substituted arylamine compounds and methods of treatment
05/10/2012US20120115848 Inhibitors of Polo-Like Kinase
05/10/2012US20120115846 Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof.
05/10/2012US20120115843 Novel pyrrolidine derivatives
05/10/2012US20120115833 Method of treating hepatocellular carcinoma
05/10/2012US20120115832 TGR5 Modulators and Methods of Use Thereof
05/10/2012US20120115831 Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
05/10/2012US20120115825 Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof
05/10/2012US20120115824 Vitamin D Receptor Agonists and Uses Thereof
05/10/2012US20120115823 Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
05/10/2012US20120115821 Composition and method for treating skin conditions
05/10/2012US20120115811 Phenylanaline amide derivatives useful for treating insulin-related diseases and conditions
05/10/2012US20120115806 Antitumor Combination Including Cabazitaxel and Capecitabine
05/10/2012US20120115804 Compositions and methods for characterizing and treating neoplasia
05/10/2012US20120115803 Treatment of acinetobacter with alginate oligomers and antibiotics
05/10/2012US20120115802 Method for using ulipristal acetate with cytochrome isozyme modulators
05/10/2012US20120115797 Peptide compositions that downregulate tlr-4 signaling pathway and methods of producing and using same
05/10/2012US20120115793 Peptidomimetic macrocycles
05/10/2012US20120115783 Peptidomimetic macrocycles
05/10/2012US20120115781 Methods For Evaluating and Implementing Prostate Disease Treatments
05/10/2012US20120115773 Modified omci as a complement inhibitor
1 ... 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 ... 2211